Financial Performance - Revenue increased by 3.9% to RMB 7,175,804 thousand compared to RMB 6,906,524 thousand in the same period last year[2] - EBITDA rose by 14.2% to RMB 2,231,943 thousand from RMB 1,953,790 thousand year-over-year[2] - Profit before tax grew by 18.0% to RMB 1,901,702 thousand compared to RMB 1,612,155 thousand in the previous year[2] - Net profit attributable to the company's owners increased by 16.1% to RMB 1,491,404 thousand from RMB 1,284,496 thousand[2] - Basic earnings per share rose by 16.1% to 82.08 RMB cents from 70.69 RMB cents[2] - Interim dividend per share increased by 33.3% to 16.0 RMB cents from 12.0 RMB cents[2] - Total revenue for the first half of 2024 reached RMB 7,175,804 thousand, a 3.9% increase from RMB 6,906,524 thousand in the same period last year[13][14] Revenue Breakdown by Product - Revenue from intermediate products increased to RMB 3,081,282 thousand, up 14.5% YoY from RMB 2,692,115 thousand[13][14] - Revenue from active pharmaceutical ingredients (API) rose to RMB 3,917,640 thousand, a 1.8% increase from RMB 3,849,116 thousand YoY[13][14] - Revenue from finished dosage products slightly decreased to RMB 2,397,777 thousand, down 1.6% from RMB 2,436,110 thousand YoY[13][14] Revenue Breakdown by Region - Revenue from China (including Hong Kong) grew to RMB 5,748,478 thousand, a 3.7% increase from RMB 5,544,083 thousand YoY[15] - Revenue from Europe decreased to RMB 411,566 thousand, down 4.6% from RMB 431,526 thousand YoY[15] - Revenue from India increased to RMB 376,958 thousand, up 13.6% from RMB 331,769 thousand YoY[15] Research and Development - Research and development expenses increased to RMB 446,800 thousand from RMB 338,678 thousand, reflecting a focus on innovation[4] - R&D expenditure increased significantly to RMB 446,800 thousand, up 31.9% from RMB 338,678 thousand YoY[13][14] Assets and Liquidity - Total assets increased to RMB 15,411,907 thousand from RMB 14,390,448 thousand, indicating growth in the company's asset base[5] - Cash and cash equivalents rose significantly to RMB 6,554,830 thousand from RMB 4,261,989 thousand, reflecting improved liquidity[5] - Total equity increased to RMB 13,573,883 thousand from RMB 12,747,618 thousand, showing growth in shareholder value[6] - The company's cash and bank balances increased to RMB 7,321,900,000 as of June 30, 2024, up from RMB 5,234,200,000 on December 31, 2023[42] - Total assets grew to RMB 22,826,100,000 as of June 30, 2024, compared to RMB 21,017,200,000 at the end of 2023[42] - Net current assets rose to RMB 7,733,500,000 as of June 30, 2024, from RMB 7,160,500,000 on December 31, 2023[42] - The company's net cash and bank balances after deducting bank borrowings and trade payables stood at RMB 3,265,100,000 as of June 30, 2024, up from RMB 1,755,500,000 at the end of 2023[42] - The company's current ratio was 2.04 as of June 30, 2024, slightly down from 2.08 on December 31, 2023[42] Debt and Borrowings - The company's interest-bearing borrowings increased to RMB 2,439,400,000 as of June 30, 2024, up from RMB 1,496,900,000 at the end of 2023[42] Government Subsidies and Foreign Exchange - Government subsidies surged to RMB 100,709 thousand, a 189.3% increase from RMB 34,809 thousand YoY[16] - Net foreign exchange gains decreased to RMB 30,773 thousand, down 39.3% from RMB 50,682 thousand YoY[18] Legal and Environmental Initiatives - The company is involved in a legal case seeking to recover RMB 340,000,000 from Chengdu Evergrande, with a partial judgment of RMB 136,300,000 awarded[45] - The company's Inner Mongolia subsidiary launched a salt separation and acid-base conversion project, expected to reduce solid waste by 6,600 tons annually and cut CO2 emissions by 45,000 tons[46] Strategic Focus - The company is focusing on consolidating core industry advantages and enhancing R&D innovation capabilities in response to China's healthcare reform[47] Employee Count - The company employs approximately 15,000 staff in Hong Kong and Mainland China, unchanged from December 31, 2023[44]
联邦制药(03933) - 2024 - 中期业绩